US FDA Holds First Hybrid Meeting With Industry
Executive Summary
A Type A meeting was held in-person with a virtual contingent, the FDA clarified to the Pink Sheet. Several other meeting requests received were eligible, but did not seek an in-person session.
You may also be interested in...
Requests For In-Person Formal Meetings With US FDA Increasing, But Will They Ever Dominate Again?
FDA data suggests sponsors still seem enamored with virtual meetings, even as the FDA expands the sessions eligible for in-person attendance.
US FDA’s No Recording Meetings Rule Already Appears Flexible
At least one sponsor has been recording meetings for several years, suggesting others could receive permission, but the decision comes with risks as well as benefits. As the agency again expands options for in-person meetings, sponsors may want to reflect on what works best for them.
US FDA’s No Recording Meetings Rule Already Appears Flexible
At least one sponsor has been recording meetings for several years, suggesting others could receive permission, but the decision comes with risks as well as benefits. As the agency again expands options for in-person meetings, sponsors may want to reflect on what works best for them.